Selatogrel Outcome Study in Suspected Acute Myocardial Infarction

Main Inclusion Criteria:

• Confirmed diagnosis of symptomatic type 1 acute myocardial infarction (AMI)ST-Elevation Myocardial Infarction (STEMI) or Non-ST-Elevation Myocardial Infarction (NSTEMI), no longer than 4 weeks prior to randomization.

• Diagnosis of multivessel coronary artery disease defined as ≥ 50% stenosis on 2 ormore coronary artery territories or on the left main artery during a prior cardiaccatheterization or cardiac catheterization during the qualifying AMI event andpresence of at least 2 of the following risk factors:

• Second prior AMI,

• Diabetes mellitus defined by ongoing glucose lowering treatment,

• Chronic kidney disease with estimated glomerular filtration rate less-than 60mL/min/1.73 m2,

• Peripheral artery disease at any time prior to randomization,

• Absence of, or unsuccessful coronary revascularization of the qualifying AMI.

• Successful self-administered placebo according to the autoinjector instruction foruse training during screening.

Main Exclusion Criteria:

• Increased risk of serious bleeding including any of the following:

• History of intracranial bleed at any time.

• Known uncorrected intracranial vascular abnormality.

• Gastrointestinal bleed requiring hospitalization or transfusion within 1 yearprior to screening.

• Already on oral triple antithrombotic therapy (i.e., Dual antiplatelet therapyand oral anticoagulant).

• Known liver impairment significantly affecting the hepatic function.

• Current dialysis.

• Ischemic stroke or transient ischemic attack within 3 months of screening.

• Chronic anemia with hemoglobin < 10 g/dL.

• Chronic thrombocytopenia with platelet count < 100,000/mm3.

• Known hypersensitivity to selatogrel, any of its excipients, or drugs of the P2Y12class.

• Previous exposure to an investigational drug within 3 months prior to randomization.

• Participation in another clinical trial with an investigational product or devicewithin 3 months prior to randomization.